AUTHOR=Mao Jiaquan , Yang Chunguang , Xin Sheng , Cui Kai , Liu Zheng , Wang Tao , Hu Zhiquan , Wang Shaogang , Liu Jihong , Song Xiaodong , Song Wen 

TITLE=Case report: Bladder preserving after maximal transurethral resection of the bladder tumor combined with chemotherapy and immunotherapy in recurrent muscle-invasive bladder cancer patients: A report of two cases

JOURNAL=Frontiers in Medicine

VOLUME=Volume 9 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.949567

DOI=10.3389/fmed.2022.949567

ISSN=2296-858X

ABSTRACT=Background
Radical cystectomy (RC) with postoperative concurrent radiotherapy is the preferred treatment option for muscle-invasive bladder cancer (MIBC). However, some patients are unable to tolerate RC or may have postoperative complications after RC and most patients require bladder-preserving treatment. There are no reports on the efficacy of maximal transurethral resection of the bladder tumor (TURBT) in combination with chemotherapy plus tislelizumab for bladder preservation in recurrent MIBC patients.
Case presentation
We report two cases diagnosed with recurrent MIBC who achieved pathological complete response (pCR) and bladder preservation after maximal TURBT combined with chemotherapy plus tislelizumab.
Conclusion
Postoperative immunotherapy should be considered for all patients with recurrent MIBC who are eligible for immunotherapy. In addition, high programmed death ligand-1 (PD-L1) expression, high tumor mutation burden (TMB), and TP53 mutation level can be combined to predict tislelizumab efficacy.